Nicotinamide Mononucleotide Derivatives And Their Uses
Patent No. EP3331894 (titled "Nicotinamide Mononucleotide Derivatives And Their Uses") was filed by Metro Biotech on Aug 5, 2016. The application was issued on Feb 17, 2021.
Patent Summary
Using nicotinamide mononucleotide (NMN) derivatives to boost NAD+ levels for treating diseases and improving cell survival. The derivatives are compounds that mimic NMN, a precursor to NAD+, and can increase NAD+ levels more than NMN alone. The derivatives have structures represented by formulas II and III. Administering these derivatives promotes intracellular NAD+ elevation for treating diseases associated with NAD+ biosynthesis deficiency. Applications include neurodegenerative diseases, stroke prevention, diabetes, lipid disorders, cardiovascular disease, aging, stress, drug toxicity, and retinal disorders.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3331894
- Application Number
- EP16833957A
- Filing Date
- Aug 5, 2016
- Status
- Opposition Rejected
- Jun 9, 2023
- Publication Date
- Feb 17, 2021
- External Links
- Slate, Register , Google Patents